acetazolamide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
56 59-66-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • acetazolamide
  • acetamox
  • acetazolamid
  • cidamex
  • nephramide
  • acetazolamide sodium
One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
  • Molecular weight: 222.24
  • Formula: C4H6N4O3S2
  • CLOGP: -0.98
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 115.04
  • ALOGS: -1.90
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.75 g O
0.75 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.64 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 90 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 75.14 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.37 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.65 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 13 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 27, 1953 FDA TEVA BRANDED PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angle closure glaucoma 153.93 17.40 39 6925 1995 50596165
Idiopathic intracranial hypertension 148.35 17.40 39 6925 2310 50595850
Hair follicle tumour benign 128.89 17.40 25 6939 362 50597798
Metabolic acidosis 118.33 17.40 71 6893 38754 50559406
Papilloedema 111.56 17.40 34 6930 3439 50594721
Intraocular pressure increased 99.93 17.40 35 6929 5481 50592679
Choroidal effusion 95.47 17.40 20 6944 434 50597726
Intracranial pressure increased 84.84 17.40 29 6935 4223 50593937
Off label use 76.15 17.40 187 6777 474239 50123921
Choroidal detachment 67.42 17.40 13 6951 182 50597978
Complications of bone marrow transplant 56.13 17.40 13 6951 453 50597707
Hepatosplenic T-cell lymphoma 53.12 17.40 13 6951 575 50597585
Macular detachment 44.24 17.40 8 6956 77 50598083
Retinal detachment 41.03 17.40 18 6946 5111 50593049
Flat anterior chamber of eye 40.21 17.40 7 6957 53 50598107
Intellectual disability 39.85 17.40 11 6953 783 50597377
Hypercapnia 39.49 17.40 17 6947 4610 50593550
Aggression 38.38 17.40 28 6936 21088 50577072
Corneal oedema 37.89 17.40 12 6952 1375 50596785
Acute generalised exanthematous pustulosis 37.03 17.40 20 6944 8918 50589242
Visual impairment 36.56 17.40 46 6918 68229 50529931
Glaucoma 36.00 17.40 24 6940 15662 50582498
Photophobia 34.70 17.40 23 6941 14864 50583296
Hypotony of eye 34.00 17.40 7 6957 139 50598021
Ophthalmic vein thrombosis 33.58 17.40 7 6957 148 50598012
Lens dislocation 31.62 17.40 5 6959 19 50598141
Visual field defect 29.87 17.40 15 6949 5764 50592396
Myopia 28.93 17.40 10 6954 1503 50596657
Cerebral venous sinus thrombosis 27.98 17.40 10 6954 1658 50596502
Persecutory delusion 27.96 17.40 11 6953 2376 50595784
Psychiatric decompensation 26.74 17.40 9 6955 1249 50596911
Retinopathy haemorrhagic 26.56 17.40 4 6960 10 50598150
Dysphoria 26.47 17.40 13 6951 4761 50593399
Myasthenic syndrome 26.28 17.40 6 6958 196 50597964
Product contamination microbial 26.05 17.40 6 6958 204 50597956
Iridocyclitis 25.97 17.40 10 6954 2039 50596121
Haemorrhagic diathesis 25.69 17.40 12 6952 3936 50594224
Vision blurred 24.50 17.40 41 6923 78606 50519554
Retroperitoneal oedema 24.24 17.40 4 6960 21 50598139
Toxic leukoencephalopathy 23.69 17.40 7 6957 636 50597524
Appetite disorder 23.44 17.40 13 6951 6101 50592059
Ocular pemphigoid 23.13 17.40 4 6960 29 50598131
CSF pressure increased 23.07 17.40 5 6959 128 50598032
Cross sensitivity reaction 22.80 17.40 9 6955 1960 50596200
Transmission of an infectious agent via product 22.68 17.40 5 6959 139 50598021
Ocular surface disease 22.57 17.40 4 6960 34 50598126
Optic disc haemorrhage 22.07 17.40 4 6960 39 50598121
Product use in unapproved indication 22.05 17.40 49 6915 115770 50482390
Drug ineffective 21.81 17.40 189 6775 819144 49779016
Arthritis infective 21.79 17.40 12 6952 5557 50592603
Acute respiratory failure 21.45 17.40 23 6941 28759 50569401
Sickle cell anaemia with crisis 21.18 17.40 11 6953 4532 50593628
Diplopia 21.09 17.40 19 6945 19241 50578919
Lactic acidosis 20.32 17.40 24 6940 33331 50564829
Acidosis 19.58 17.40 14 6950 10213 50587947
Meningitis aseptic 19.20 17.40 10 6954 4142 50594018
Conjunctival hyperaemia 18.93 17.40 8 6956 2074 50596086
Foetal exposure during pregnancy 18.88 17.40 21 6943 27338 50570822
Vitreous disorder 18.78 17.40 4 6960 94 50598066
Dropped head syndrome 18.36 17.40 4 6960 105 50598055
Splenomegaly 17.98 17.40 13 6951 9647 50588513
Skin warm 17.97 17.40 10 6954 4725 50593435
Retinal vascular occlusion 17.88 17.40 5 6959 373 50597787
Nasal flaring 17.70 17.40 3 6961 19 50598141

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraocular pressure increased 159.59 21.07 46 3269 4743 29566469
Choroidal detachment 128.98 21.07 24 3291 343 29570869
Metabolic acidosis 109.32 21.07 62 3253 37600 29533612
Angle closure glaucoma 98.55 21.07 22 3293 803 29570409
Choroidal effusion 86.66 21.07 15 3300 138 29571074
Toxic epidermal necrolysis 63.93 21.07 34 3281 18119 29553093
Congenital emphysema 48.58 21.07 6 3309 0 29571212
Ocular surface disease 42.65 21.07 7 3308 45 29571167
Visual acuity reduced 41.75 21.07 24 3291 14852 29556360
Hyphaema 37.00 21.07 9 3306 479 29570733
Glaucoma 35.79 21.07 16 3299 5841 29565371
Drug ineffective 31.12 21.07 100 3215 363070 29208142
Hypochloraemia 31.10 21.07 8 3307 535 29570677
Burkholderia test positive 30.60 21.07 9 3306 990 29570222
Corneal oedema 29.42 21.07 9 3306 1133 29570079
Acidosis hyperchloraemic 28.93 21.07 7 3308 364 29570848
Photocoagulation 27.99 21.07 4 3311 8 29571204
Drug reaction with eosinophilia and systemic symptoms 26.01 21.07 23 3292 27969 29543243
Trabeculectomy 25.57 21.07 4 3311 18 29571194
Product contamination microbial 25.47 21.07 7 3308 604 29570608
Off label use 24.05 21.07 81 3234 300719 29270493
Dysmetria 23.40 21.07 6 3309 396 29570816
Crystalluria 23.21 21.07 6 3309 409 29570803
Hypocapnia 22.90 21.07 5 3310 164 29571048
Transmission of an infectious agent via product 22.62 21.07 5 3310 174 29571038
Hypercapnia 22.19 21.07 10 3305 3716 29567496
Visual acuity tests abnormal 21.98 21.07 4 3311 50 29571162
Corneal opacity 21.95 21.07 6 3309 507 29570705
Endophthalmitis 21.38 21.07 9 3306 2839 29568373
Intraocular pressure decreased 21.12 21.07 4 3311 63 29571149

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angle closure glaucoma 243.58 15.92 60 9274 2597 64486801
Intraocular pressure increased 203.85 15.92 67 9267 8235 64481163
Choroidal detachment 203.31 15.92 39 9295 503 64488895
Choroidal effusion 168.46 15.92 34 9300 578 64488820
Metabolic acidosis 142.90 15.92 102 9232 70856 64418542
Hair follicle tumour benign 130.71 15.92 26 9308 409 64488989
Idiopathic intracranial hypertension 128.74 15.92 36 9298 2557 64486841
Off label use 88.96 15.92 245 9089 632561 63856837
Papilloedema 87.03 15.92 32 9302 5473 64483925
Intracranial pressure increased 83.08 15.92 33 9301 6956 64482442
Ocular surface disease 62.55 15.92 11 9323 84 64489314
Hypercapnia 60.24 15.92 27 9307 7667 64481731
Corneal oedema 57.85 15.92 19 9315 2324 64487074
Glaucoma 53.76 15.92 32 9302 16316 64473082
Complications of bone marrow transplant 51.48 15.92 13 9321 622 64488776
Toxic epidermal necrolysis 49.77 15.92 42 9292 37124 64452274
Transmission of an infectious agent via product 49.10 15.92 10 9324 178 64489220
Hepatosplenic T-cell lymphoma 48.15 15.92 13 9321 809 64488589
Product contamination microbial 47.23 15.92 13 9321 870 64488528
Hyphaema 46.19 15.92 12 9322 643 64488755
Photophobia 44.59 15.92 29 9305 17264 64472134
Macular detachment 43.06 15.92 9 9325 183 64489215
Visual impairment 42.52 15.92 53 9281 74024 64415374
Drug ineffective 41.46 15.92 234 9100 840013 63649385
Retinal detachment 41.10 15.92 21 9313 7955 64481443
Visual acuity reduced 39.10 15.92 32 9302 27109 64462289
Flat anterior chamber of eye 38.84 15.92 8 9326 151 64489247
Vision blurred 37.20 15.92 55 9279 90261 64399137
Ophthalmic vein thrombosis 36.51 15.92 8 9326 205 64489193
Myopia 34.51 15.92 12 9322 1746 64487652
Endophthalmitis 33.20 15.92 16 9318 5349 64484049
Acidosis hyperchloraemic 31.59 15.92 9 9325 683 64488715
Hypotony of eye 30.36 15.92 7 9327 227 64489171
Cerebral venous sinus thrombosis 30.12 15.92 11 9323 1844 64487554
Acidosis 29.96 15.92 23 9311 17772 64471626
Visual field defect 29.56 15.92 17 9317 8129 64481269
Corneal opacity 29.21 15.92 9 9325 896 64488502
Acute generalised exanthematous pustulosis 27.76 15.92 20 9314 14038 64475360
Trabeculectomy 27.32 15.92 5 9329 49 64489349
Photocoagulation 26.36 15.92 4 9330 10 64489388
Iridocyclitis 24.84 15.92 11 9323 3034 64486364
Retinal vascular occlusion 24.75 15.92 7 9327 517 64488881
Vitreous disorder 24.70 15.92 6 9328 244 64489154
Intellectual disability 24.17 15.92 8 9326 1002 64488396
Retroperitoneal oedema 24.04 15.92 4 9330 21 64489377
Dysphoria 23.91 15.92 12 9322 4376 64485022
Diplopia 23.67 15.92 24 9310 26741 64462657
Lens dislocation 22.75 15.92 5 9329 130 64489268
Appetite disorder 22.16 15.92 13 9321 6448 64482950
Multiple-drug resistance 22.08 15.92 13 9321 6489 64482909
Blindness 21.80 15.92 21 9313 21998 64467400
Somnolence 20.99 15.92 71 9263 203574 64285824
Meningitis aseptic 20.90 15.92 12 9322 5718 64483680
Psychiatric decompensation 20.42 15.92 9 9325 2454 64486944
CSF pressure increased 20.25 15.92 5 9329 218 64489180
Retinopathy haemorrhagic 20.22 15.92 4 9330 61 64489337
Drug resistance 19.94 15.92 25 9309 35077 64454321
Burkholderia test positive 19.71 15.92 6 9328 573 64488825
Myasthenic syndrome 19.08 15.92 6 9328 639 64488759
Sickle cell anaemia with crisis 19.01 15.92 11 9323 5321 64484077
Aggression 18.80 15.92 28 9306 46204 64443194
Optic disc haemorrhage 18.79 15.92 4 9330 89 64489309
Eye pain 18.73 15.92 23 9311 31602 64457796
Intraventricular haemorrhage 18.72 15.92 10 9324 4143 64485255
Persecutory delusion 18.71 15.92 10 9324 4148 64485250
Prostaglandin analogue periorbitopathy 18.70 15.92 3 9331 12 64489386
Haemorrhagic diathesis 18.66 15.92 11 9323 5503 64483895
Arthritis infective 18.64 15.92 12 9322 7018 64482380
Acute respiratory failure 18.55 15.92 29 9305 49905 64439493
Visual acuity tests abnormal 17.71 15.92 4 9330 118 64489280
Product use in unapproved indication 17.69 15.92 61 9273 176557 64312841
Brain stem haematoma 17.68 15.92 4 9330 119 64489279
Crystalluria 17.53 15.92 6 9328 832 64488566
Punctate keratitis 17.35 15.92 6 9328 859 64488539
Dysmetria 17.14 15.92 6 9328 890 64488508
Drug reaction with eosinophilia and systemic symptoms 16.78 15.92 29 9305 54188 64435210
Respiratory alkalosis 16.50 15.92 9 9325 3888 64485510
Conjunctival hyperaemia 16.49 15.92 9 9325 3890 64485508
Hyperventilation 16.48 15.92 11 9323 6829 64482569
Pupillary block 16.43 15.92 3 9331 29 64489369

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01EC01 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Carbonic anhydrase inhibitors
FDA CS M0020790 Sulfonamides
FDA MoA N0000000235 Carbonic Anhydrase Inhibitors
FDA EPC N0000175517 Carbonic Anhydrase Inhibitor
MeSH PA D000927 Anticonvulsants
MeSH PA D002257 Carbonic Anhydrase Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004232 Diuretics
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D045283 Natriuretic Agents
CHEBI has role CHEBI:23018 EC 4.2.1.1 inhibitor
CHEBI has role CHEBI:35498 diuretics
CHEBI has role CHEBI:35623 anticonvulsants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Malignant glaucoma indication 10100008
Anoxia due to high altitude indication 42883007
Absence seizure indication 79631006
Open-angle glaucoma indication 84494001 DOID:1067
Secondary glaucoma indication 95717004
Edema indication 267038008
Peripheral edema indication 271809000
Angle-closure glaucoma indication 392291006 DOID:13550
Peripheral Edema due to Chronic Heart Failure indication
Metabolic alkalosis off-label use 1388004
Myoclonic seizure off-label use 37356005
Idiopathic intracranial hypertension off-label use 68267002 DOID:11459
Benign intracranial hypertension off-label use 68267002 DOID:11459
Familial hypokalemic periodic paralysis off-label use 82732003 DOID:14452
Epilepsy off-label use 84757009 DOID:1826
Obstructive hydrocephalus off-label use 230746009 DOID:14159
Familial periodic paralysis off-label use 267607008 DOID:1029
Tonic-clonic epilepsy off-label use 352818000 DOID:7725
Simple partial seizure off-label use 117891000119100
Urine Alkalinization off-label use
Hydrocephalus due to Intraventricular Hemorrhage off-label use
Mixed Epilepsy off-label use
Renal tubular acidosis contraindication 1776003 DOID:14219
Respiratory acidosis contraindication 12326000
Hyperkalemia contraindication 14140009
Metabolic acidosis, normal anion gap, acidifying salts contraindication 18104000
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Decreased respiratory function contraindication 80954004
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Disease of liver contraindication 235856003 DOID:409
Disorder of electrolytes contraindication 237840007
Primary adrenocortical insufficiency contraindication 373662000
Recurrent Calcium Renal Calculi contraindication




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Mild congestive heart failure Indication
Dogs Rapid reduction of intraocular pressure Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Vetamox Soluble Powder Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.04 acidic
pKa2 9.21 acidic
pKa3 1.84 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Carbonic anhydrase 12 Enzyme INHIBITOR Ki 8.60 CHEMBL CHEMBL
Carbonic anhydrase 1 Enzyme INHIBITOR Ki 7.92 CHEMBL CHEMBL
Carbonic anhydrase 4 Enzyme INHIBITOR Ki 7.96 CHEMBL CHEMBL
Carbonic anhydrase 2 Enzyme INHIBITOR Ki 8.48 CHEMBL CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 7.22 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 7.27 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 8.60 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 8.51 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 7.96 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 7.39 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 8.24 CHEMBL
Carbonic anhydrase Enzyme Ki 9.10 CHEMBL
Carbonic anhydrase V Enzyme Ki 8.74 CHEMBL
Carbonic anhydrase-related protein 11 Enzyme Ki 8.24 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 8.05 CHEMBL
Aquaporin-1 Transporter WOMBAT-PK
Carbonic anhydrase Enzyme Ki 7.70 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 7.77 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 7.15 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 7.80 CHEMBL
Carbonic anhydrase Enzyme Ki 7.22 CHEMBL
Carbonic anhydrase Enzyme Ki 4.92 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.14 CHEMBL
Carbonic anhydrase Enzyme Ki 7.09 CHEMBL
Carbonic anhydrase Enzyme Ki 7.40 CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme Ki 7.92 CHEMBL
Carbonic anhydrase Enzyme Ki 7.96 CHEMBL
Alpha carbonic anhydrase Enzyme Ki 7.80 CHEMBL
Endochitinase Enzyme Ki 4.68 CHEMBL
Carbonic anhydrase Enzyme Ki 7.13 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 8 CHEMBL
Carbonic anhydrase Enzyme Ki 5.24 CHEMBL
Astrosclerin-3 Enzyme Ki 7.29 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 6.60 CHEMBL
Delta carbonic anhydrase Unclassified Ki 7.08 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 8.05 CHEMBL
Carbonic anhydrase 2 Enzyme IC50 6.02 CHEMBL
Carbonic anhydrase Enzyme IC50 7.80 CHEMBL
Carbonic anhydrase Enzyme Ki 7.57 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 4.08 CHEMBL
Carbonic anhydrase Enzyme Ki 7.56 CHEMBL
Carbonic anhydrase Enzyme Ki 7.12 CHEMBL
Carbonic anhydrase, alpha family Unclassified Ki 8.37 CHEMBL
Carbonate dehydratase Enzyme Ki 8.35 CHEMBL
Carbonic anhydrase 2, isoform A; LD26647p Enzyme Ki 7.11 CHEMBL
Carbonic anhydrase 1; GH09688p Enzyme Ki 6.97 CHEMBL

External reference:

IDSource
4017898 VUID
N0000146250 NUI
D00218 KEGG_DRUG
1424-27-7 SECONDARY_CAS_RN
167 RXNORM
C0000981 UMLSCUI
CHEBI:27690 CHEBI
AZM PDB_CHEM_ID
CHEMBL20 ChEMBL_ID
DB00819 DRUGBANK_ID
CHEMBL1200814 ChEMBL_ID
D000086 MESH_DESCRIPTOR_UI
1986 PUBCHEM_CID
481 INN_ID
6792 IUPHAR_LIGAND_ID
O3FX965V0I UNII
2596 MMSL
4121 MMSL
814 MMSL
d00161 MMSL
002286 NDDF
002287 NDDF
4017898 VANDF
4017899 VANDF
33664007 SNOMEDCT_US
372709008 SNOMEDCT_US
72469007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9006 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 20 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9503 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 20 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9503 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 20 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0527-1050 TABLET 250 mg ORAL ANDA 19 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6663 TABLET 250 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6663 TABLET 250 mg ORAL ANDA 18 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-567 TABLET 250 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 16729-331 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 21 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-120 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 11 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-287 TABLET 125 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-287 TABLET 125 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-288 TABLET 250 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-288 TABLET 250 mg ORAL ANDA 18 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-313 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 16 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-787 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 12 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 29033-030 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 22 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 39822-0190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 13 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 42291-089 TABLET 125 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 42291-090 TABLET 250 mg ORAL ANDA 18 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 42291-103 TABLET 250 mg ORAL ANDA 19 sections
ACETAZOLAMIDE EXTENDED-RELEASE HUMAN PRESCRIPTION DRUG LABEL 1 42571-243 CAPSULE 500 mg ORAL ANDA 21 sections
ACETAZOLAMIDE EXTENDED-RELEASE HUMAN PRESCRIPTION DRUG LABEL 1 42571-243 CAPSULE 500 mg ORAL ANDA 21 sections
Acetazolamide Human Prescription Drug Label 1 46708-349 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 21 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 50090-0577 TABLET 125 mg ORAL ANDA 19 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 50090-3003 TABLET 250 mg ORAL ANDA 19 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 50090-3003 TABLET 250 mg ORAL ANDA 19 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 50090-3132 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 11 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 50090-4511 TABLET 125 mg ORAL ANDA 18 sections
Acetazolamide Human Prescription Drug Label 1 50090-5217 TABLET 125 mg ORAL ANDA 18 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 50090-5593 TABLET 250 mg ORAL ANDA 17 sections